This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG511CA_L.jpg
Pfizer said it will make non-controlling investments in the biotechs with small- to medium-sized market capitalizations, but did not identify them.
The move comes at a time when the COVID-19 pandemic has led drugmakers to delay their clinical trials testing various therapies.
Pfizer said its Breakthrough Growth Initiative program, under which it was making the investment, allows partner companies to access its research, clinical development and manufacturing resources.
